Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Authors
Andersen, KarlIssue Date
2013
Metadata
Show full item recordCitation
Curr. Hypertens. Rep. 2013, 15 (5):484-8Abstract
Hypertension is an established risk factor for stroke, premature coronary artery disease and heart failure. Control of elevated blood pressure has been shown to result in significant reduction of cardiovascular risk. Aldosterone, the final product of the renin-angiotensin-aldosterone system (RAAS), not only causes salt and water reabsorbtion in the kidneys through its effect on the mineralocorticoid hormone receptor (MR), but also an MR-independent effect, not regulated by conventional MR blockade. Although many pharmacological agents target different levels of the RAAS cascade, these generally result in elevated renin concentration and plasma renin activity. This upstream feedback response subsequently results in elevated levels of angiotensin II, a potent vasoconstrictor and stimulus to aldosterone release. This aldosterone breakthrough counteracts the long-term blood pressure-lowering effect of these agents. Therefore the development of a new class of pharmacologic agents that directly inhibit the production of aldosterone may prove clinically useful in reducing aldosterone and thereby controlling elevated blood pressure.Additional Links
http://link.springer.com/article/10.1007/s11906-013-0379-7#page-1http://dx.doi.org/10.1007/s11906-013-0379-7
Rights
Archived with thanks to Current hypertension reportsae974a485f413a2113503eed53cd6c53
10.1007/s11906-013-0379-7
Scopus Count
Collections
Related articles
- Aldosterone synthase inhibition in humans.
- Authors: Azizi M, Amar L, Menard J
- Issue date: 2013 Jan
- Therapeutic perspectives in hypertension: novel means for renin-angiotensin-aldosterone system modulation and emerging device-based approaches.
- Authors: Unger T, Paulis L, Sica DA
- Issue date: 2011 Nov
- [Does the rennin inhibitor aliskiren offer promising novel opportunities in the treatment of cardiovascular diseases?].
- Authors: Horký K
- Issue date: 2007 Apr
- Dual renin-angiotensin-aldosterone blockade: promises and pitfalls.
- Authors: Chrysant SG, Chrysant GS
- Issue date: 2015 Jan